WO2026099761 - PEPTIDES
National phase entry is expected:
Publication Number
WO/2026/099761
Publication Date
15.05.2026
International Application No.
PCT/IB2025/061314
International Filing Date
05.11.2025
Title **
[English]
PEPTIDES
[French]
PEPTIDES
Applicants **
SALEM, Yahya Ahmed
Inventors
SALEM, Yahya Ahmed
Priority Data
PCT/EG2024/050030
06.11.2024
EG
2513099.8
11.08.2025
GB
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2596 | |
| EPO | Filing, Examination, Granting | 9331 | |
| Japan | Filing, Examination, Granting | 2370 | |
| South Korea | Filing, Examination, Granting | 2411 | |
| USA | Filing, Examination, Granting | 6140 |
Total:
22,848
Contact Us
Abstract[English]
Provided are polyarginine polypeptide ASIC inhibitors, pharmaceutical compositions comprising the same as well as methods and uses therefor In particular, the present disclosure relates to the methods and uses of such polypeptides or pharmaceutical compositions in the treatment of ASIC-related diseases. Such polypeptides or pharmaceutical compositions are useful to treat neurological disorders, neurodegenerative diseases, psychological disorders, sexual disorders, cardiovascular diseases, respiratory diseases, inflammatory diseases, renal diseases, gastrointestinal diseases, metabolic disorders, cancer, and addiction, e.g. smoking addiction.[French]
L'invention concerne des inhibiteurs d'ASIC polypeptidiques de polyarginine, des compositions pharmaceutiques les comprenant, ainsi que des procédés et des utilisations de ceux-ci. En particulier, la présente divulgation concerne des procédés et des utilisations de tels polypeptides ou compositions pharmaceutiques dans le traitement de maladies associées à ASIC. De tels polypeptides ou compositions pharmaceutiques sont utiles pour traiter des troubles neurologiques, des maladies neurodégénératives, des troubles psychologiques, des troubles sexuels, des maladies cardiovasculaires, des maladies respiratoires, des maladies inflammatoires, des maladies rénales, des maladies gastro-intestinales, des troubles métaboliques, un cancer et l'addiction, par exemple l'addiction au tabagisme.